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Abstract
Migraine is a common and burdensome neurological condition which affects mainly female patients during their
childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in
the main European Guidelines. Previous (2014) European recommendations on limiting the use of valproate in
women of childbearing age did not achieve their objective in terms of limiting the use of valproate in women of
childbearing age and raising awareness regarding the hazardous effect of valproate to children exposed in utero.
The teratogenic and foetotoxic effects of valproate are well documented, and more recent studies show that there
is an even greater neurodevelopmental risk to children exposed to valproate in the womb. The latest 2018
European review from the European Medicines Agency, with the active participation of the European Headache
Federation, concluded that not enough has been done to mitigate the risks associated with in utero exposure to
valproate. The review called for more extensive restrictions to the conditions for prescribing, better public
awareness, and a more effective education campaign in migrainous women.
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Introduction
Migraine, gender and evolution to chronicity
Migraine is one of the most common non-communicable
diseases, ranked as the most debilitating disease worldwide
in under 50s by the Global Burden of Diseases 2016 [1, 2].
Migraine affects over 14% of adults worldwide, presents a
higher prevalence in women (M:F ratio 1:2–3) with an
estimated progression to the chronic form in about 1–4%
of the population [3, 4]. In women aged 15–49 years, mi-
graine is the top cause of years lived with disability [1, 2].
Typical migraine crises, which may be up to 3 days
long, are characterised by nausea, vomiting, photophobia
and phonophobia, and worsen with physical activity.
Evolution into the chronic form of migraine is present
mainly in female patients and its sequelae may include
medication overuse [1].
Treatment of headaches in pregnancy and effects of
headache medications on the child during pregnancy
and breastfeeding have been reviewed recently [5].
During pregnancy and breastfeeding the preferred thera-
peutic strategy should be a non-pharmacological one [6].
Valproate and migraine
Valproate has been indicated to treat epilepsy since 1967
and to treat bipolar disorders in Europe since 1995. In
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some European countries valproate is also indicated in
prophylaxis of migraine attacks.
Guidelines regarding treatments for acute migraine and
preventive therapies have been developed by the Head-
ache and Neurology Societies [7, 8]. Valproate is included
in the existing clinical guidelines of the European Feder-
ation of Neurological Societies [9] and of the European
Headache Federation [10] as one of the therapies for
migraine prophylaxis.
Valproate is frequently used for the treatment of
pre-chronic and chronic migraine, complicated or not by
medication overuse. (The prevalence of medication over-
use migraine is about 2% of the entire population with
chronic migraine [11] and data summarised from various
studies suggest that a year after withdrawal and detoxifi-
cation, 40–60% will relapse [12]).
This publication consists of four sections. The first pre-
sents the 2014 European review on the effects of valproate
in children exposed in utero; the second includes the main
data that question the effectiveness of the measures and
recommendations agreed in 2014; the third presents the
2018 updated measures and recommendations; and finally
section four summarises the main material which the
physicians will use during implementation of the updated
recommendations.
European review in 2014
In October 2014, the Pharmacovigilance and Risk Assess-
ment Committee (PRAC), a scientific committee of the
European Medicines Agency (EMA) concluded a review
[13] on the safety and efficacy of valproate and related
substances in female children, women of childbearing po-
tential and pregnant women. The review, which looked at
all available data from non-clinical, clinical and phar-
macoepidemiological studies, published literature, spon-
taneous reports as well as the views of relevant experts
(i.e. in neurology, psychiatry, child neuropsychiatry, ob-
stetrics etc.), led to the outcomes summarised below.
Firstly, data derived from a meta-analysis [14] (in-
cluding registries and cohort studies) confirmed the
already known risk of congenital malformations. Al-
most 11% (10.73% [95% CI: 8.16–13.29]) of children of
epileptic women exposed to valproate monotherapy
during pregnancy suffer from congenital malforma-
tions. The risk of major malformations in the general
population is about 2–3%. The risk is dose-dependent,
but a threshold dose, below which no risk exists, cannot
be established based on the current data. The incidence
of risk appears to be higher with valproate alone or in
combination than with other anti-epileptic drugs
(AEDs) alone. The most common types of malforma-
tions included neural tube defects, facial dysmorphism,
cleft lip and palate, craniostenosis, cardiac, renal and
urogenital defects, limb defects (including bilateral
aplasia of the radius), and multiple anomalies involving
various body systems.
Secondly, data have also shown that exposure to val-
proate in utero can have adverse effects on mental and
physical development of exposed children. This risk also
seems to be dose-dependent, and a threshold dose,
below which no risk exists, can again not be established
based on available data. The exact gestational period at
risk for these effects is uncertain and the possibility of a
risk throughout the entire pregnancy cannot be ex-
cluded. Studies in preschool children exposed in utero
to valproate show that up to 30–40% of them experience
delays in their early development such as talking and
walking later, lower intellectual abilities, poor language
skills (speaking and understanding) and memory prob-
lems [15–19]. Intelligence quotient (IQ) measured in
school aged children (age 6) with a history of valproate
exposure in utero was on average 7–10 points lower
than those of children exposed to other anti-epileptics.
Although the role of confounding factors cannot be
excluded completely, this risk in children exposed to
valproate may be independent from maternal IQ [18].
Available data show that children exposed to valproate
in utero are at increased risk of autistic spectrum dis-
order (approximately three-fold) and childhood autism
(approximately five-fold) compared with the general
population. Limited data suggests that children exposed
to valproate in utero may in addition be more likely to
develop symptoms of attention deficit/hyperactivity dis-
order (ADHD) [19].
As a result, based on all the evidence available, in 2014
PRAC recommended restrictions on the use of valproate
due to the risk of malformations and neurodevelopmen-
tal problems in children exposed to valproate in the
womb [13].
Regarding the management of migraine prophylaxis,
it was noted that there are only limited data on the
efficacy of valproate. The PRAC concluded that val-
proate should be contraindicated in the prophylaxis
of migraine attacks in pregnancy or in women of
childbearing age who are not using effective methods
of contraception.
Changes to the product information including contra-
indications, warnings and precautions, and updated in-
formation on the risks related to exposure during
pregnancy to inform the clinicians and women, were
agreed. Educational materials for healthcare profes-
sionals and patients were recommended.
Finally, the pharmaceutical companies for valproate
were requested to perform studies to assess the effective-
ness of the recommended risk minimisation measures
and to further characterise the prescribing patterns for
valproate with a pre- and post-implementation analysis
and assessment.
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Recent data on effectiveness of the current risk
minimisation measures in women of childbearing age
Fast forward a few years from the 2014 recommenda-
tions and new data started coming to light on the effect-
iveness of the implemented risk minimisation measures
from various sources, including a drug utilisation study
(DUS) and a healthcare professional survey, both per-
formed by the pharmaceutical companies who market
valproate in Europe. It is important to note that the
period after implementation of the risk minimisation
measures (2015–2016) is rather short and the DUS study
is not completed yet. The preliminary data nonetheless
suggested that prescribing behaviour changed after im-
plementation of the risk minimisation measures. How-
ever there was additional data forthcoming from the
joint healthcare professional survey (completed) which
indicated that there was room for improvement regard-
ing the knowledge and behaviour of the prescribers.
In addition, a number of national initiatives were under-
taken in European countries and input from professional
and patient representative organisations provided infor-
mation useful for the evaluation of the effectiveness of the
risk minimisation measures.
The Agence nationale de sécurité du médicament et des
produits de santé (ANSM) in France performed a national
pharmacoepidemiological study (CNAMTS study - part I)
[20] covering all indications of valproate products (based
on data from French national medico-administrative data-
bases), together with a national survey conducted in
pharmacies.
The results of the French study provided evidence
that, despite the measures recommended following the
European review in 2014, exposure of women of child-
bearing age to valproate had persisted in the country in
the reported period including a high level of exposure
during pregnancy (2 in 1000 pregnancies were exposed
to valproate between 2007 and 2014).
Furthermore the results from the French survey con-
ducted between April and June 2016 in a sample of 222
community pharmacies showed that prescribing condi-
tions were not adhered to, especially in the bipolar dis-
order indication. Conditions regarding supply and use
were adhered to in only 36% of the products dispensed
among girls and women of childbearing age who had
been prescribed valproate by a psychiatrist.
Although limited, the results from studies and surveys
consistently indicated that the risk minimisation mea-
sures of 2014 did not have a satisfactory impact on pre-
scribing patterns.
In addition the results also indicated that the switching
rates for transfer to other medication in patients at risk
were not high enough.
Although these observations were identified mainly in
the epilepsy and bipolar disorder indications, there are
no reasons or data to indicate that these results cannot be
extrapolated also to the indication of migraine prophylaxis.
Data from all these different sources further confirm
the need for improved risk communication among pre-
scribers and patients.
Reinforcement of the risk minimisation measures and
update of the clinical recommendations following the
2018 review
In the light of the above the PRAC carried out a further
review of the risks and measures to manage them,
resulting in new recommendations issued in 2018 [21].
Here only those recommendations relevant to the indi-
cation on prophylaxis of migraine are discussed, and
specifically the measures that require the involvement of
the physician for their implementation in collaboration
with the patient. Further details of the full recommenda-
tions can be found in the publicly available assessment
report of the latest 2018 European review [21].
Updates to the product information were deemed to
be necessary in order to reduce valproate exposure dur-
ing pregnancy. The risks of congenital malformations
and neurodevelopmental are, and will always remain
inherent to valproate, and cannot be reduced or elimi-
nated. However by reducing or minimizing exposure
during pregnancy these risks can be mitigated.
The PRAC recommended the contraindication of
valproate treatment during pregnancy in the indication
of bipolar disorders [21, 22] and maintained its 2014
recommendation of contraindication of valproate treat-
ment during pregnancy in the prophylaxis of migraine
attacks [13], in order to protect the unborn child from a
major risk of congenital malformations and neurodeve-
lopmental disorders.
The PRAC also recommended several measures as
part of pregnancy prevention programme (PPP) to ad-
here to.
First of all, the individual patient circumstances should
be evaluated in each case to guarantee engagement. The
treating physician should discuss the therapeutic options
with each patient and ensure her understanding of the
risks of treatment with valproate and the measures
needed to minimise these risks. The patient needs to
acknowledge that she has understood the hazards and
necessary precautions associated with valproate use and
sign a risk acknowledgement form.
During the consultation the patient must understand
the need to undergo pregnancy testing prior to initiation
of treatment and during treatment, as needed.
It is essential to ensure that the patient is counselled
regarding contraception. Assessment also is needed that
the patient is capable of complying with the requirement
to use effective contraception without interruption
during the entire duration of treatment with valproate.
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Before contraception is discontinued, the patient must
consult her physician as soon as she is planning preg-
nancy to ensure timely discussion of switching to alter-
native treatment options prior to conception and so the
need for migraine treatment can be re-evaluated. In case
of unplanned pregnancy the patient should urgently
consult with her physician to organise the discontinu-
ation of the migraine treatment.
As the personal circumstances of the patient may
change, regular (at least annual) reviews of treatment
need to be performed by a specialist experienced in the
management of migraine.
These PPP conditions also concern women who are
not currently sexually active unless the prescriber con-
siders that there are compelling reasons to indicate that
there is no risk of pregnancy.
Educational measures are necessary in order to ensure
that both the clinical community and patients are in-
formed about the risks of valproate in pregnant women
and women of childbearing age, and about the measures
necessary to eliminate the risk of exposure on valproate
in pregnancy.
Educational materials
In this publication, only the material relevant to prescribers
is mentioned. A full list of the educational materials can be
found in the published assessment report [21].
Guide for healthcare professionals
The development of an improved healthcare profes-
sional guide is due following the 2018 review. This
guide will explain the PPP and its conditions. It will ex-
plain the requirements prior to starting treatment with
valproate, the modalities for annual re-assessment of
the need for valproate therapy, and discontinuation or
switching to alternative treatment options for female
children who experience menarche and women of
childbearing potential.
Recommendations on switching or discontinuing
valproate treatment, as well as recommendations on
pregnancy planning, will support provision of this
information to patients.
Actions to mitigate the risks associated with the use of
valproate in case of pregnancy will also be included.
This guide should allow prescribers to familiarise
themselves with the more recent data on disorders
of development in the exposed child, provide infor-
mation about the risks of valproate monotherapy
and poly-therapy and a description of the roles of
different healthcare professionals. It should also pro-
vide instructions to the prescribers on the distribu-
tion of the patient guide and the completion of the
risk acknowledgment form.
Annual risk acknowledgment form
As part of the PPP, an annual risk acknowledgment form
will be made available to support the transmission of
information to the patient and foster the dialogue be-
tween the prescriber and the patient. This form will
ensure that the information has been given and that it is
understood by the patient.
The form will include a checklist for prescribers and pa-
tients (or carers). The checklist is intended to be used by
physicians at the time of treatment initiation, and at the
annual review to facilitate discussion with female patients
about the suitability of valproate treatment and its risks.
This acknowledgment form will cover information
about the risk to the unborn baby in case of in utero
exposure to valproate, the need for negative pregnancy
test at treatment initiation, the need for effective contra-
ception without interruption throughout the entire dur-
ation of treatment with valproate (if of childbearing
potential). It will also require that the patient contacts
her physician once she decides to plan for a pregnancy,
to ensure timely discussion of alternative treatment op-
tions prior to conception and before contraception is
discontinued, and that she contacts her doctor immedi-
ately for an urgent treatment review in case of suspected
or inadvertent pregnancy.
Guide for patients
The development of an improved guide for women who
are being prescribed valproate and are able to get preg-
nant, is also in progress. Although this document is
addressed to patients it is summarised here as treating
physicians may be requested to provide this guide
directly to their patient.
The guide will provide comprehensive information on
risks to the unborn child due to in utero exposure to
valproate, the details of the PPP and the required actions
in case of pregnancy or intention to become pregnant.
In order to provide adequate information, it will address
different situations in the patient journey and be
age-appropriate: from first prescription, women continu-
ing valproate treatment but not trying to have a child,
women of childbearing potential continuing valproate
treatment and considering trying to have a child, and
pregnant women (unplanned pregnancy). Information
about the annual risk acknowledgement form and the
patient card which has also been developed should be
included in the patient guide.
Conclusions
Migraine and chronic headaches occur frequently in the
population and more specifically in women. In case of
pregnancy the treatment of migraine may be complicated
due to the risk of certain medications. For the preventive
treatments there are fewer options available to physicians.
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Valproate has a place in the pharmaceutical armament-
arium for the prophylaxis of migraine attacks, according
to several clinical guidelines.
Valproate treatment should be initiated with caution
in young females and women of child-bearing potential
in view of the risks to the foetus in the event of exposure
to valproate during pregnancy.
In view of the risks for the unborn child when ex-
posed to valproate in utero, valproate should only be
used as last line medication for prophylaxis of migraine
attacks in female children, adolescents and women of
childbearing potential.
Adherence to the PPP is essential. Pregnancy should be
excluded before start of any treatment with valproate, and
as appropriate later on. The patient should be counselled
regarding contraception, but also assessed to ensure she
can comply with the use of effective contraception with-
out interruption during the entire duration of treatment
with valproate. In case of unplanned pregnancy, valproate
treatment should be discontinued as soon as possible. The
information on the risks in case of an unplanned
pregnancy should be explained to the patient at the
first prescription and then at least annually for the
duration of the treatment.
Together, the clinician and patient should discuss the
need for regular (at least annual) review of her treatment
by a specialist experienced in the management of mi-
graine. This discussion should be documented via the
risk acknowledgement form.
The importance of the patient consulting her physician
as soon as she is planning a pregnancy needs to be
emphasised. This will enable a timely discussion to take
place between the physician and the patient to ensure
switching to alternative treatment options prior to con-
ception and before contraception is discontinued.
Clinical guidelines need to be reviewed and, potentially,
updated to further improve the awareness of physicians
on the risks of valproate.
Finally, continuous interaction between the European
Medicine Agency and European Headache Federation, as
an eligible healthcare professional organisation dedicated
to migraine, can facilitate the reduction of unnecessary ex-
posure to valproate in migrainous women of childbearing
age, via provision of better education materials for both
physicians and patients suffering from migraine.
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